{
  "id": 1068708,
  "title": "CDMOs Expand and Build for Future Growth",
  "url": "https://urgent.news/2026/08/15/cdmos-expand-and-build-for-future-growth",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-15T15:51:36.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/bioprocessing/cdmos-expand-and-build-for-future-growth/"
  },
  "original_language": "en",
  "account": "Five contract development and manufacturing organizations (CDMOs) have recently expanded their services and built new facilities, incorporating artificial intelligence (AI) into their operations. Fujifilm Biotechnologies, which opened its $3.2 billion biomanufacturing facility in Holly Springs, NC last year, has been selected for the FDA's PreCheck Pilot Program, aimed at strengthening pharmaceutical manufacturing capabilities. The company plans to double its bioreactor capacity with an additional $1.2 billion investment by 2028. Fujifilm Holly Springs currently employs about 800 people, with an anticipated growth to 1,400 once the second phase is completed. The facility's first customer for the second phase is immunology drug developer argenx, which will manufacture drug substances for Vyvgart and Vyvgart Hytrulo. Fujifilm also recently opened a 2,000-square-meter QC laboratory at its commercial-scale manufacturing site in Hillerød, Denmark, with 100 Quality team members conducting various tests and implementing a laboratory information management system (LIMS). In Madison, WI, Fujifilm Cellular Dynamics opened a new 175,000-square-foot facility dedicated to human induced pluripotent stem cells (iPSCs) development and manufacturing. Lonza Group is also expanding its AI capabilities, hiring 20 to 30 AI-focused professionals to enhance their expertise in drug discovery, development, clinical trial processes, and molecule design. Additionally, Lonza is enhancing its aseptic drug product capacity in Stein by adding another commercial-scale multi-purpose filling line for antibody-drug conjugates.",
  "summary": "Executives from Fujifilm Biotechnologies, Lonza Group, MilliporeSigma, Samsung Biologics, and Thermo Fisher Scientific discuss their companies' recent service expansions and new facilities in interviews with GEN. The post CDMOs Expand and Build for Future Growth appeared first on GEN - Genetic Engineering and Biotechnology News .",
  "key_points": [
    "Fujifilm Biotechnologies expands biomanufacturing capacity by $1.2 billion by 2028.",
    "Fujifilm Holly Springs anticipates workforce growth from 800 to 1,400 employees.",
    "Lonza Group hires AI professionals to enhance drug discovery and development."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}